VJHemOnc Podcast

Leading experts in the field of myeloma, Keith Stewart and Gareth Morgan, share highlights from day one of the Myeloma 2022 meeting. They discuss updates in measurable residual disease (MRD) and prognosis, antibody therapy for amyloidosis, new drugs, immune system drugs, single cell sequencing, and the potential of genomics in myeloma and cancer treatment.

Leading expert Uwe Platzbecker discusses immune dysregulation in myelodysplastic syndromes (MDS) and the development of novel targeting strategies. Topics include IRAC inhibition, NLRP3 and CD47 targeting, innate immune pathways, potential future treatments for MDS and AML, and the importance of identifying biomarkers.

Noelle Frey, an expert in CAR-T therapy and leukemia treatment, discusses the future of CAR-T therapy in ALL. Topics include the impact of tisagenlecleucel approval, promise of allogeneic products, improving response durability, reducing relapses, targeting multiple antigens, and off-the-shelf therapy for ALL.

Leading experts Lawrence Boise and Paola Neri discuss novel targets in multiple myeloma, including RAS and PIKfyve. They also talk about the epigenomics and epigenetics of resistance to proteasome inhibitors and IMiDs, as well as PROTAC therapy for difficult to manipulate targets.

Experts discuss key updates in the treatment and management of myeloproliferative neoplasms (MPNs), including improvements in pathology visualization, use of machine learning, clinical trials for therapeutic agents, and potential combinations of JAK inhibitors. They also cover the development of a vaccine, long-term data on Ropegg in polycythemia vera, and exploring drug combinations for myelofibrosis treatment.

Angela Dispenzieri, expert in amyloidosis treatment and diagnosis, discusses the importance of early diagnosis and raising awareness of AL amyloidosis. She highlights the superior results shown by the combination regimen of dara tumumab, cyclophosphamide, bortezimib, and dexamethasone in clinical trials. The podcast explores unmet needs in the field, emphasizes the importance of supportive care and expertise in amyloid centers, and discusses ongoing clinical trials and the potential of immunotherapy and Veneta Clax in treating AL amyloidosis.

UK experts Graham Jackson and Martin Kaiser discuss myeloma treatment in the UK, focusing on the importance of genomics and key updates from trials like OPTIMUM and MASTER. Topics include treatment regimens for high-risk patients, timely treatment and therapy continuation, and the significance of collaborations and insights from chromosome analysis.

Experts discuss recent updates in lymphoma and CLL treatment in the UK, including trials like POLARIX, FLAIR, and MARIETTA. They highlight novel agents, potential side effects, and the future of lymphoma treatment. The FLAIR study comparing Ibruttanib and FCR is discussed, along with the benefits of a-calibrutinib in CNS prophylaxis.

The podcast discusses the importance of early interception and intervention in multiple myeloma. It emphasizes the need for early screening, risk stratification, and precision interception. The discussion also focuses on treating precursor conditions, identifying high-risk populations, and utilizing clinical markers and genomics to predict myeloma risk.

Christian Chabannon, a leading expert in blood and marrow transplantation, and Anna Sureda discuss the impact of COVID-19 pandemic on the European Society for Blood and Marrow Transplantation (EBMT). They review the challenges faced by EBMT during the pandemic and how it affected transplantation practices. They also explore the relevance of stem cell transplantation in CAR-T therapy and outline EBMT's future projects.